Abelson murine leukemia virus (A-MuLV) is a replication-defective, transforming retrovirus that arose in a steroid-treated BALB/c mouse injected with Moloney murine leukemia virus (M-MuLV) (1) . The virus induces a fatal nonthymic lymphosarcoma 3 to 4 weeks after injection into neonatal mice and transforms both fibroblasts and hematopoietic cells in vitro (18, 21) . A-MuLV stocks always contain a replication-competent virus (such as M-MuLV) that provides the defective A-MuLV with enzymatic functions and structural proteins (9, 21) .
The defective nature of A-MuLV was demonstrated directly by Scher and Siegler (21) when they isolated an A-MuLV-transformed nonproducer cell line called ANN-1. A-MuLV rescued from ANN-1 cells with cloned helper virus induced typical Abelson lymphosarcomas, indistinguishable from the disease induced by the uncloned virus prepared from tumor extracts. ANN-i-derived virus thus became widely used and served as the prototype cloned AMuLV strain.
Heteroduplex mapping and Si nuclease mapping studies using ANN-i-derived A-MuLV show that the 5.6-kilobase A-MuLV RNA genome has two regions of precise homology with M-MuLV: a 730-base region at the 3' end and a 1,320-base region at the 5' end (D. Baltimore, A Shields, G. Otto, S. Goff, P. Besmer, 0. Witte, and N. Rosenberg, Cold Spring Harbor Symp. Quant. Biol., in press; A. Shields, G. Otto, S. Goff, M. Paskind, and D. Baltimore, submitted for publication). The 3.5-kilobase region in the center of the A-MuLV genome is not homologous to M-MuLV, and hybridization studies show that this region is not present in other replication-defective murine retroviruses (8; Baltimore et al., in press). These A-MuLV sequences are present in normal mouse DNA and probably represent a portion of the genome of the BALB/c mouse from which A-MuLV was originally isolated. Because these sequences distinguish A-MuLV from its M-MuLV parent and other murine retroviruses, they may be responsible for the unique biological properties of A-
MuLV.
Analysis of the proteins expressed in ANN-1 cells and A-MuLV-transformed cells derived using virus recovered directly or indirectly from ANN-1 cells has identified a single protein of 120,000 molecular weight (P120) that is encoded by the 5.6-kilobase genomic RNA of A-MuLV (18, 19, 26) . This protein contains some of the determinants of the M-MuLV gag gene products (p15, p12, and a part of p30), and the remaining 90,000 molecular weight is made up of A-MuLVspecific sequences (25; Baltimore et al., in press). These A-MuLV-specific sequences share serological determinants with a normal mouse cellular protein of 150,000 molecular weight (NCP-150) that is present in spleen, thymus, and bone marrow (25a 
MATERIALS AND METHODS
Cells and viruses. Routine maintenance of cell cultures has been described elsewhere (16, 17 (16) and adapted to grow in liquid culture as previously described (17) . Clones of A-MuLV-transformed fibroblasts were derived by plating the infected cells in microtiter wells after a 1.5-h adsorption period. The trypsinized cells were plated at a concentration of 0.3 to 0.4 cell per well.
All virus stocks were prepared from 24-h culture fluids and passed through 0.45-,um filters before use. The titers of focus-forming virus in A-MuLV stocks were determined using NIH/3T3 cells (21) . Titers of helper virus were determined by assay on S+L-cells (2) or by the XC plaque assay (20) .
A-MuLV(P120) (i.e., A-MuLV producing a 120,000-molecular-weight A-MuLV-specific protein) was prepared using ANN-1 cells superinfected with M-MuLV clone 1 (5) . A-MuLV(P160) was prepared using RAW309Cr cells or NIH/3T3 cells transformed by filtered culture fluids from RAW309Cr. The RAW309Cr cells used in these experiments release AMuLV in combination with an NB-tropic, XC plaquepositive helper virus (data not shown) that is probably related to the M-MuLV in the original A-MuLV tumor extracts. A-MuLV(P100) and A-MuLV(P90) were derived from clones of Ab-NRK cells that had been treated with 10 ,ug of fluorodeoxyuridine per ml for 4 days before cloning. The A-MuLV was rescued from these nonproducer clones by using the amphototropic virus isolate 292 (12) and passed onto NIH/3T3 cells. The resulting transformed cultures of NIH/3T3 cells were used for routine virus production.
Protein labeling studies. All radiochemicals were purchased from New England Nuclear Corp., Boston, Mass. Techniques for labeling, immunoprecipitation, and gel electrophoresis have been described in detail elsewhere (22, 24, 25 (27) . A cell extract was prepared from 107 cells by using lysis buffer (10 mM NaPO4, pH 7.5, 100 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate [SDS]) at 0°C and clarified at 100,000 x g for 2.5 h. Antisera were added to the extract, and the immunoprecipitates were collected with Staphylococcus aureus (6) and analyzed on SDS-polyacrylamide gels (7) developed by fluorography (3).
Antisera used were rabbit anti-M-MuLV reverse transcriptase/p15, rabbit anti-M-MuLV gp7O, goat anti-Rauscher MuLV p12, goat anti-Rauscher plO, goat anti-M-MuLV virion, mouse anti-AbT, rabbit anti-mouse immunoglobulin (a gift of V. Sato), and rabbit anti-calf TdT serum. The characterization of these reagents has been described elsewhere (22, 24-26; A. Silverstone, L. Sun, 0. N. Witte, and D. Baltimore, submitted for publication). Virus proteins and TdT were examined by electrophoresis of immunoprecipitates through 10% polyacrylamide gels; immunoglobulin molecules were examined in the presence of 2-mercaptoethanol on 12.5% gels and in the absence of 2-mercaptoethanol on 5 to 20% gradient gels.
RESULTS
Detection of a strain of A-MuLV producing a larger form of P120. The A-MuLVencoded P120 protein has been expressed in all of the more than 100 different lymphoid and fibroblast transformed cells we have examined (26; Rosenberg and Witte, unpublished data). These cell lines were all derived in vitro in a similar fashion, either by cloning infected cells at limiting dilution, in the case of the fibroblasts, or by using the agarose transformation assay (16) for lymphoid cells. In the case of lymphoid cells, all of the cell lines expressed a similar set VOL. 33, 1980 on October 27, 2017 by guest http://jvi.asm.org/ Downloaded from of differentiation markers and are probably analogous to primitive cells related to B lymphocytes (22, 23) . The A-MuLV used in all of these experiments was derived either directly or indirectly from ANN-1 cells.
To investigate the universality of P120 expression, we examined two A-MuLV-transformed cell lines isolated from tumor tissue by two other laboratories. Two cell lines expressing different phenotypic markers were used: the ABPC-22 cell line, a typical immunoglobulin-secreting plasmacytoma (9) , and RAW39OCr, a macrophage line (11) .
[35S]methionine-labeled cell extracts from these cell lines were immunoprecipitated with antisera specific for M-MuLV and AMuLV proteins and analyzed by electrophoresis (Fig. 1) . The previously described lymphoblastoid 2M3 cell line (17, 26) produced P120 that reacted with anti-p15, anti-p30, and anti-AbT sera (Fig. 1C) . However, the ABPC-22 myeloma B ! 2 3 4 5 6 4 :a cell line (Fig. 1D ) and the macrophage cell line RAW309Cr (Fig. 1A ) both did not produce P120, but did produce a 160,000-molecular-weight protein (P160) that was precipitated with anti-p15, anti-p30, and anti-AbT sera. The weak precipitation of P160 with anti-p30 serum was not observed consistently. A typical lymphoblastoid cell line isolated by infecting spleen cells with virus from RAW309Cr, the R5 cell line (Fig. 1B) , also produced P160. Thus, P160 expression was not related to the highly differentiated phenotypes expressed by RAW309Cr and ABPC-22 cells.
A more complete survey of the serological determinants present on P160 is shown in Fig. 2 . Immunoprecipitation of P160 from the R5 spleen cell line showed that the protein contained determinants of p15, p12, and p30, but not plO. Anti-AbT serum (lane 7) but not normal mouse serum (lane 6) also precipitated P160. In Precipitates were collected with S. aureas, denatured, and analyzed on a 10%o SDS-polyacrylamide gel developed by fluorography (3, 6, 7) .
3) a n t g p Fig. 3 . Extracts from a nonproducer cell line synthesizing P90 were precipitated with the MMuLV gag gene reagents anti-p15, anti-p12, and anti-p30 sera (Fig. 3A, lanes 2, 3, and 4) , but not by anti-plO serum (Fig. 3A, lane 5) . P90 was also precipitated by anti-AbT serum (Fig. 3A, lane  6) . A similar pattern of precipitation was obtained when extracts from a producer cell line synthesizing P100 were examined (Fig. 3B) . This molecule reacted with anti-p15, anti-p30, and anti-p12 sera (Fig. 3B, lanes 2, 3, and 4 ) and antiAbT (Fig. 3B, lane 6 ), but not with anti-plO serum (Fig. 3B, lane 5) . Both proteins reacted with anti-M-MuLV virion serum (lane 1), and neither reacted with anti-gp7O serum (lane 7).
The presence of A-MuLV-specific determinants in P90 was demonstrated in a blocking experiment (Fig. 4) which showed that P90 was precipitated with anti-AbT (Fig. 4B, lane 1) alone or with anti-AbT in the presence of 60 or 180 ,ug of M-MuLV virion proteins (lanes 2 and 3). P90 precipitation via gag gene determinants with anti-M-MuLV serum (Fig. 4A, lane 1 (Fig. 4A, lanes 2 and 3) . P100 molecules also had A-MuLV-specific determinants that could be demonstrated in blocking experiments with anti-AbT serum (data not shown).
Retrospective examination of AbNRK-1 cells and the culture of NIH/3T3 cells transformed by mass infection with AbNRK-1-derived AMuLV showed that all of these cells synthesized P100. The NIH/3T3 culture transformed by mass infection with Ab-NRK-3-derived AMuLV synthesized both P120 and P90, but only P120 could be detected in Ab-NRK-3 cells.
Thus, although a stable change in the A-MuLV genome in the fluorodeoxyuridine-treated cells does not appear related to the altered morphology of some of these cells, this screening procedure did result in the recovery of altered P120-like proteins.
Stability of the A-MuLV variants. Virus stocks from A-MuLV-transformed cells synthesizing the various sizes of proteins were used to transform a series of new clones to determine whether the size ofthe A-MuLV-specific protein was a stable, heritable trait. Clones of both fibroblasts and bone marrow cells derived using A-MuLV(P160) and A-MuLV(P100) synthesized the appropriate proteins (Table 1) . In addition, a new series of ANN-1-derived A-MuLV clones were also examined, and all of these clones synthesized P120 (Table 1) and P120 in this cell line detected by metabolic labeling indicate that P90 is the predominant species (data not shown). The P160 molecule is the largest A-MuLVspecific protein we have found; this A-MuLV strain may be the parental A-MuLV isolate. To determine whether P120 was a chance isolate in the ANN-1 nonproducer or represented a second major variant of A-MuLV, we analyzed the size of the A-MuLV-specific protein in a series of clones derived from a tumor extract similar to those used in the original Scher and Siegler (21) experiments that led to the isolation of ANN-1.
The A-MuLV in this tumor extract (a gift of R. Siegler) descended from original material given time in passage at which this extract was prepared.
Lymphoid-specific markers expressed by A-MuLV-transformed clones. Previous work has established the presence of lymphoid-specific gene markers in A-MuLV-transformed lymphoid cells (4, 9, 11, 22, 23) . Direct biochemical and immunological assays have demonstrated the presence of the markers TdT and intracellular immunoglobulin in many cell lines (22, 23) . The frequency of expression of immunoglobulin and TdT was monitored in A-MuLVtransformed bone marrow clones to determine whether the transformed cells derived using the different A-MuLV strains were similar. Clones derived using A-MuLV(P90) and A-MuLV-(P160) were analyzed along with a new series of A-MuLV(P120) clones. Bone marrow cells from C57BL/6J, C57L/J, and BALB/cAn mice were used for the transformation studies. The presence of immunoglobulin and TdT was determined by SDS-polyacrylamide gel analysis of [3S]methionine-labeled immunoprecipitates (Fig. 5 ). Consistent with observations described elsewhere, the anti-calf TdT serum used here precipitated a 60,000-molecular-weight protein from murine cell lines synthesizing TdT (Silverstone et al., submitted for publication). The antimouse immunoglobulin serum used here precipitated immunoglobulin M (IgM) and IgG from cell lines synthesizing these proteins (22) .
Screening of a large number of lymphoid clones showed that most of them synthesized TdT (Table 2 ). About 60% of the clones synthesized immunoglobulin in the form of ,u heavy chain (Table 1) . No 7 to 8S IgM molecules or free light-chain molecules were detected in any of the clones analyzed here. The frequency of immunoglobulin-positive clones and the presence of, heavy chain in the absence of light chain is consistent with earlier observations (22) . As shown in Table 2 , no strain-specific differences were seen when the frequency of immunoglobulin and TdT expression was tabulated according to the A-MuLV isolate used to transform the clones. In addition, when these data were reanalyzed with respect to the mouse strain 4) were labeled and prepared as described in Fig. 1 , then immunoprecipitated with 5 ,ul of rabbit anti-TdT (A) and a polyvalent rabbit anti-mouse immunoglobulin (B). Samples were processed as described in Fig. 1 . TdT expression was analyzed on a 10% SDS-polyacrylamide gel, and immunoglobulin expression was analyzed on a 12.5% SDS-polyacrylamide gel. used as a source of bone marrow cells, no mouse strain-specific differences in the frequency of marker expression were evident (data not shown). DISCUSSION All of the A-MuLV-transformed cell lines we have examined synthesize an A-MuLV-specific protein that contains M-MuLV gag gene-derived sequences. All of the molecules are nonglycosylated phosphoproteins, and the size of the different proteins is stable upon cloning. Although these proteins vary in size from 160,000 to 90,000 molecular weight, they are similar in their structure, being made up of the M-MuLVderived p15, p12, and part of the p30 protein in addition to an A-MuLV-specific region. Because the proteins contain the same gag gene-derived determinants, they probably vary in the size of their A-MuLV-specific region. If the A-MuLVspecific region of these polyproteins contains the transforming sequences, the A-MuLV(P90) strain places a maximum limit on the size of this region. Because P90 resembles P120 in structure, about 30,000 molecular weight of P90 is probably derived from the M-MuLV gag gene products p15, p12, and p30 (26; Baltimore et al., in press). Thus, the remaining 60,000 molecular weight of P90, the A-MuLV-specific sequences, is sufficient to encode for any transforming functions these sequences direct. In addition, the similarity of lymphoid markers expressed by clones transformed with all of these isolates shows that the addition of sequences in A-MuLV(P160) and the loss of sequences in A-MuLV(P90) does not affect target cell selection.
The P160 strain of A-MuLV appears to be a naturally occurring isolate that probably is the predominant component of A-MuLV stocks maintained at the National Institutes of Health by passage of tumor extracts. R. Risser and D. Grunwald, using A-MuLV derived from the National Institutes of Health pool of virus, have identified a 160,000-molecular-weight protein that expresses p12 determinants in some of their A-MuLV-induced tumors (R. Risser, personal communication). This protein is probably the same as the P160 described here.
The P160 protein probably contains about 130,000 molecular weight of A-MuLV-specific sequences; based on the ability of A-MuLV(P90) to transform cells, over half of these sequences must not be required to transform cells in vitro.
Whether these sequences are beneficial to the virus growth and oncogenicity in vivo is unclear. However, the predominance of A-MuLV(P120) in another tumor extract virus pool indicates that A-MuLV(P160) is not always selected by in vivo passage. Whether differences in the passage history of the Boston and National Institutes of Health pools of A-MuLV are important in the derivation of two A-MuLV strains cannot be ascertained at this time.
The genomes of the new A-MuLV strains have not been fully characterized. However, the 3.6-kilobase central region of the A-MuLV(P120) genome is large enough to encode 130,000 molecular weight of protein. Thus, if the AMuLV(P160) genome is the same size as the AMuLV(P120) genome, P160 would account for the entire coding capacity of the genome.
The origin of the shorter A-MuLV proteins is unclear. The possible role of fluorodeoxyuridine treatment in their origin must be considered. although neither P100 or P90 appears to be directly related to the morphological variations observed in the fluorodeoxyuridine-treated cells, 20 random Ab-NRK clones did not synthesize smaller forms of P120 (0. Witte The lymphoid marker survey also indicates that the cells susceptible to A-MuLV in the bone marrow of BALB/cAn, C57BL/6J, and C57L/J mice are probably similar. This result is significant because these three strains differ in their susceptibility to A-MuLV-induced tumors, BALB/c being susceptible and C57BL/6J and C57L being resistant (15 
